[{"orgOrder":0,"company":"Emzor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emzor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emzor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emzor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Emzor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emzor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emzor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emzor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Swiss Pharma Nigeria Limited","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NIGERIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Swiss Pharma Nigeria Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Pharma Nigeria Limited \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"6","companyTruncated":"Swiss Pharma Nigeria Limited \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"Kintampo Health Research Centre, Ghana","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ Kintampo Health Research Centre, Ghana","highestDevelopmentStatusID":"1","companyTruncated":"London School of Hygiene & Tropical Medicine \/ Kintampo Health Research Centre, Ghana"}]

Find Clinical Drug Pipeline Developments & Deals for Sulfadoxine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Swiss Pharma Nigeria Limited

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Swiss Pharma Nigeria Limited

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 26, 2024

                          Lead Product(s) : Sulfadoxine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Medicines for Malaria Venture

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          London School of Hygiene & Tropical Medicine

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          London School of Hygiene & Tropical Medicine

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 26, 2023

                          Lead Product(s) : Sulfadoxine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Kintampo Health Research Centre, Ghana

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Emzor Pharmaceutical

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Emzor Pharmaceutical

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 11, 2022

                          Lead Product(s) : Sulfadoxine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Emzor Pharmaceutical

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Emzor Pharmaceutical

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 08, 2020

                          Lead Product(s) : Sulfadoxine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Federal Medical Centre, Owo

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Federal Medical Centre, Owo

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 09, 2019

                          Lead Product(s) : Sulfadoxine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank